By Dr Richard Shute There is no doubt that the interest and hype around blockchain or distributed ledger technology (DLT) builds daily. The explosion of articles and books recently is testament to this. But what is a blockchain and how might DLT impact healthcare, Pharma and R&D? Running through the… Read More
Oral Peptide Therapeutics - A Holy Grail or Quixotic Quest? By Dr Paul Shields Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and peptides are the building blocks of life… Read More
Nanoparticles & Nanomedicines - Exploring The Past, Present and Future By Professor Yvonne Perrie & Dr Euan Ramsay Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines. Read More
Novel Drug Targets From Phenotypic Screening By Dr Jim Freeth, Dr Elizabeth Kingsley & Jo Soden Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug… Read More
How The B6 Mouse Strain is Revolutionising Drug Discovery By Dr Philip Dube Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research. Understanding the B6… Read More
The Rise of Immunotherapies - Strategies to Accelerate Their Advance Into Clinical Trials By Edward Cribb The striking rise of immunotherapies in the past decade has had a transformative effect on the prospects for the treatment of patients with cancer. Also referred to as biologic therapies, immunotherapies are a new… Read More
Tackling Multi-Drug Resistant Bacteria By Dr Ankit Mahadevia Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such as beta-lactam, tetracyclines… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More
Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired, efficacious but yet safe effect in… Read More
Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. By weaponising the… Read More
A Marriage of Technologies for Immuno-Oncology In Vivo Studies By Dr Philip Dube Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation. Read More
Immuno-Oncology's Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs… Read More
Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. Read More
Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved… Read More
3D Cellular Imaging - Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing… Read More
An Update on Hepatitis B Therapies By Dr John Sullivan-Bolyai The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant burden it places on communities across the globe, hepatitis… Read More